Title: Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with
colorectal cancer: an overview of case reports/case series and meta-analysis of prevalence
studies
Version: 1 Date: 10 Nov 2024
Reviewer:  Rajdeep Singh
Reviewer's report:
Manuscript Review:
Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with
colorectal cancer: a systematic review and meta-analysis.
The manuscript does a good job in analyzing how common these bacteria are in people with
colorectal cancer (CRC) around the world. Since there’s increasing evidence that gut bacteria
play a role in cancer, this study is timely. The authors took a thorough approach, searching
databases from 2000 to 2024 and applying solid meta-analytic methods, which adds weight to
their findings.
Their results show some interesting trends, like the higher prevalence of F. nucleatum in Asia
and B. fragilis in Europe among CRC cases. They also point out how these findings could be
useful in developing therapies that target gut bacteria, which is a popular area of research right
now. Another interesting point is the difference in prevalence between genders, with men having
higher rates of these bacteria, which could help in creating more focused screening efforts.
That said, there are a few limitations. For example, there aren’t enough studies from Africa
and Oceania, which means the results don’t fully cover the global population. Also, the study
couldn’t explore how these bacteria might relate to specific stages of CRC, so it doesn’t give us
a full picture of how they might influence cancer progression. But despite these limitations, this
manuscript provides valuable insights into the role of these bacteria in CRC and could pave the
way for future research on using microbiota as part of cancer treatment.
In short, this systematic review and meta-analysis is a helpful addition to CRC research
focused on the microbiome. Addressing some of the current gaps in research could make our
understanding of bacterial involvement in CRC even stronger. The manuscript is well-structured,
and the findings offer a good starting point for further studies in this field. I would suggest it
looks good for submission.
Thank you
Dr. Rajdeep Singh MD, FACP
Clinical Assistant Professor, WSU
Hospitalist , Peacehealth Medical Group
Title: Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with
colorectal cancer: an overview of case reports/case series and meta-analysis of prevalence
studies
Version: 1 Date: 10 Nov 2024
Reviewer:  Rajdeep Singh
Reviewer's report:
Manuscript Review:
Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with
colorectal cancer: a systematic review and meta-analysis.
The manuscript does a good job in analyzing how common these bacteria are in people with
colorectal cancer (CRC) around the world. Since there’s increasing evidence that gut bacteria
play a role in cancer, this study is timely. The authors took a thorough approach, searching
databases from 2000 to 2024 and applying solid meta-analytic methods, which adds weight to
their findings.
Their results show some interesting trends, like the higher prevalence of F. nucleatum in Asia
and B. fragilis in Europe among CRC cases. They also point out how these findings could be
useful in developing therapies that target gut bacteria, which is a popular area of research right
now. Another interesting point is the difference in prevalence between genders, with men having
higher rates of these bacteria, which could help in creating more focused screening efforts.
That said, there are a few limitations. For example, there aren’t enough studies from Africa
and Oceania, which means the results don’t fully cover the global population. Also, the study
couldn’t explore how these bacteria might relate to specific stages of CRC, so it doesn’t give us
a full picture of how they might influence cancer progression. But despite these limitations, this
manuscript provides valuable insights into the role of these bacteria in CRC and could pave the
way for future research on using microbiota as part of cancer treatment.
In short, this systematic review and meta-analysis is a helpful addition to CRC research
focused on the microbiome. Addressing some of the current gaps in research could make our
understanding of bacterial involvement in CRC even stronger. The manuscript is well-structured,
and the findings offer a good starting point for further studies in this field. I would suggest it
looks good for submission.
Thank you
Dr. Rajdeep Singh MD, FACP
Clinical Assistant Professor, WSU
Hospitalist , Peacehealth Medical Group
Please review this paper.
user
Title: Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with
colorectal cancer: an overview of case reports/case series and meta-analysis of prevalence
studies
Version: 1 Date: 10 Nov 2024
Reviewer:  Rajdeep Singh
Reviewer's report:
Manuscript Review:
Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with
colorectal cancer: a systematic review and meta-analysis.
The manuscript does a good job in analyzing how common these bacteria are in people with
colorectal cancer (CRC) around the world. Since there’s increasing evidence that gut bacteria
play a role in cancer, this study is timely. The authors took a thorough approach, searching
databases from 2000 to 2024 and applying solid meta-analytic methods, which adds weight to
their findings.
Their results show some interesting trends, like the higher prevalence of F. nucleatum in Asia
and B. fragilis in Europe among CRC cases. They also point out how these findings could be
useful in developing therapies that target gut bacteria, which is a popular area of research right
now. Another interesting point is the difference in prevalence between genders, with men having
higher rates of these bacteria, which could help in creating more focused screening efforts.
That said, there are a few limitations. For example, there aren’t enough studies from Africa
and Oceania, which means the results don’t fully cover the global population. Also, the study
couldn’t explore how these bacteria might relate to specific stages of CRC, so it doesn’t give us
a full picture of how they might influence cancer progression. But despite these limitations, this
manuscript provides valuable insights into the role of these bacteria in CRC and could pave the
way for future research on using microbiota as part of cancer treatment.
In short, this systematic review and meta-analysis is a helpful addition to CRC research
focused on the microbiome. Addressing some of the current gaps in research could make our
understanding of bacterial involvement in CRC even stronger. The manuscript is well-structured,
and the findings offer a good starting point for further studies in this field. I would suggest it
looks good for submission.
Thank you
Dr. Rajdeep Singh MD, FACP
Clinical Assistant Professor, WSU
Hospitalist , Peacehealth Medical Group
assistant